|
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
|
Jul 2014
|
Leuk Res Rep
|
myelodysplastic syndromes (MDS)
|
|
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents
|
Dec 2015
|
Leuk Res.
|
myelodysplastic syndromes (MDS)
|
|
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
|
Jan 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
|
May 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Distinct iron architecture in SF3B1 mutant myelodysplastic syndromes patients is linked to an SLC25A37 splice variant with a retained intron
|
May 2014
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related myelodysplastic syndromes-specific risk stratification: Are we putting the cart before the horse?
|
Jul 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Whole exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
|
Dec 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood - a prospective study by EWOG-MDS.
|
Jun 2013
|
Leukemia
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Rethinking clinical trial endpoints in myelodysplastic syndromes.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
|
Feb 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
